Effects of EDP-420 on penicillin-resistant and quinolone- and penicillin-resistant pneumococci in the rabbit meningitis model

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 665-669

  Stucki, Armin ^a   Gerber, Peter ^a   Acosta, Fernando ^b   Cottagnoud, Marianne ^b   Cottagnoud, Philippe ^a   Jiang, Lijiang ^c   Nguyen, Phong ^c   Wachtel, Derek ^c   Wang, Guoqiang ^c   Phan, Ly T ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b Clinic of Internal Medicine   (Switzerland)

^c Enanta Pharmaceuticals Inc   (United States)

Author keywords

Ketolide; Pneumococcal meningitis; Resistance

Indexed keywords

9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; CEFTRIAXONE; PENICILLIN G; QUINOLONE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PENETRATION; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; RABBIT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BRIDGED COMPOUNDS; DISEASE MODELS, ANIMAL; MACROLIDES; MENINGITIS, BACTERIAL; PENICILLIN RESISTANCE; PENICILLINS; QUINOLONES; RABBITS; STREPTOCOCCUS PNEUMONIAE;

EID: 40049107141     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm505     Document Type: Article

References (14)

1. Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998; 26: 1188-95.
2. Felmingham D, Reinert RR, Hirakata Y et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002; 50 Suppl S1: 25-37.
3. Farrell DJ, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. J Clin Microbiol 2007; 45: 290-3.
4. Kaplan SL, Mason EO Jr. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 1998; 11: 628-44.
5. Martinez-Lacasa J, Cabellos C, Martos A et al. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 2002; 49: 507-13.
6. Dacey RG, Sande MA. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 1974; 6: 437-41.
7. Gerber CM, Cottagnoud M, Neftel KA et al. Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain. Eur J Clin Microbiol Infect Dis 1999; 18: 866-70.
8. Cottagnoud P, Acosta F, Cottagnoud M et al. Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. Antimicrob Agents Chemother 2000; 44: 2179-81.
9. Maglio E, Sun H, Patel T et al. Pharmacodynamics of a new bridged bicyclic ketolide (BBK) EP-13420 in a murine S. pneumoniae (SPN) model. In: Interscience Conference on Antimicrobials and Chemotherapy, Washington, DC, 2004. Poster F 1407, p. 219.
10. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46.
11. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide. Telithromycin. J Infect 2002; 44 Suppl A: 3-10.
12. Phan L. In: Interscience Conference on Antimicrobials and Chemotherapy, Washington, DC, 2004. Poster E 1858.
13. Xiong L, Korkhin Y, Mankin AS. Binding site of the bridged macrolides in the Escherichia coli ribosome. Antimicrob Agents Chemother 2005; 49: 281-8.
14. Scomeaux B, Arya A, Polemeropoulos A et al. In vitro and in vivo evaluation of EP-13420: A novel ketolide highly active against resistant pathogens and having exceptional pharmacokinetic properties in the dog. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003. F-1191.